Kirk G. Nielsen - 09 Feb 2026 Form 4/A - Amendment Insider Report for SpyGlass Pharma, Inc. (SGP)

Role: Director
Signature: /s/ Steven Schwen, as attorney-in-fact for Kirk Nielsen
Issuer symbol: SGP
Transactions as of: 09 Feb 2026
Net transactions value: $0
Form type: 4/A - Amendment
Filing time: 11 Feb 2026, 17:13:35 UTC
Date Of Original Report: 10 Feb 2026
Previous filing: 05 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Nielsen Kirk G.	Director	C/O SPYGLASS PHARMA, INC. 27061 ALISO, CREEK RD., SUITE 100, ALISO VIEJO	/s/ Steven Schwen, as attorney-in-fact for Kirk Nielsen	11 Feb 2026	0001523522

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	SGP	Common Stock						3,310,619	09 Feb 2026	See footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Shares	Change %	Date	Underlying Class	Amount	Ownership	Footnotes
transaction	SGP	Series B Preferred Stock	Conversion of derivative security	-1,690,230	-100%	09 Feb 2026	Common Stock	1,690,230	See footnote	F1, F2
transaction	SGP	Series C-1 Preferred Stock	Conversion of derivative security	-548,067	-100%	09 Feb 2026	Common Stock	548,067	See footnote	F1, F2
transaction	SGP	Series C-2 Preferred Stock	Conversion of derivative security	-548,067	-100%	09 Feb 2026	Common Stock	548,067	See Footnote	F1, F2
transaction	SGP	Series D Preferred Stock	Conversion of derivative security	-359,255	-100%	09 Feb 2026	Common Stock	359,255	See Footnote	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date.
F2	These shares are held directly by Vensana Capital I, L.P. ("Vensana I"). Vensana Capital I GP, LLC ("Vensana GP I") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the "GP I Managing Directors") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of the these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Content

All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date.

These shares are held directly by Vensana Capital I, L.P. ("Vensana I"). Vensana Capital I GP, LLC ("Vensana GP I") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the "GP I Managing Directors") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of the these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Remarks:

This amended Form 4 amends and restates Table II of the Form 4 filed by the Reporting Person on February 10, 2026 (the "Prior Form 4") and is being filed to correct the number of shares reported in Column 5 of Table II of the Prior Form 4 to reflect the Issuer's preferred stock converted on a one-for-one basis into shares of the Issuer's Common Stock prior to the closing of the Issuer's initial public offering of its Common Stock.